Introduction Skin rash is the most common adverse effect in patients with cancer receiving epidermal growth factor receptor inhibitors (EGFRIs), which can impair quality of life and lead to treatment discontinuation. Numerous primary studies have explored factors that may predict the development of skin rash.
However, the wide range of variables and substantial heterogeneity among these studies limit the availability of high-quality, synthesised evidence. A comprehensive scoping review is therefore warranted to systematically map and synthesise the risk factors for EGFRI-induced skin rash in patients with cancer.
Methods and analysis This scoping review will be conducted following the Joanna Briggs Institute methodology and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews checklist. An initial search strategy was developed and piloted in PubMed.
The comprehensive search will include PubMed, Embase, Web of Science Core Collection, CINAHL Ultimate, CENTRAL (Cochrane Central Register of Controlled Trials), SinoMed, CNKI (China National Knowledge Infrastructure) and Wanfang Database.
BMJ Open published a clinical update in Research Highlights on 07 Apr 2026.
The item focuses on Risk factors for skin rash among patients with cancer receiving epidermal growth factor receptor inhibitors: a scoping review protocol.
Review the original article for the full source wording and details.